By Topic
Pacific Edge (ASX: PEB): Testing Critical Resistance, Breakout or Reversal Ahead?
Pacific Edge (ASX: PEB) tests critical resistance near 0.240 after surging on draft Medicare coverage, a 75% increase in reimbursement rates, and a NZ$25.4 million capital raise. Strong volume supports the rally, but RSI near 70 warns of potential pullback risk.
Stakk (ASX: SKK) Surges on Growth Momentum After Record Revenue Expansion
Stakk (ASX: SKK) has surged, reporting record $5.52 million in March quarter revenue and 186% growth, driven by its Stakk IQ embedded finance platform. Expanding across Australian and U.S. banks, healthcare, and regulated industries, it secured major contracts, lifting ARR toward A$26 million.
Can Hammer Metals (ASX: HMX) Sustain Its Breakout Above Long-Term Resistance?
Hammer Metals, a junior explorer focused on copper, gold and lithium in Queensland and WA, broke above resistance on strong Kalman drilling and a trading halt tied to a potential control deal, though overbought technicals and exploration risk remain.
Is Alterity Therapeutics (ASX: ATH) Stabilising After Volatility at a Key Technical Level?
Alterity Therapeutics (ASX: ATH) is advancing its lead neurodegeneration drug, ATH434, toward Phase 3 trials. Following positive clinical data and a 1-for-50 share consolidation, the stock is holding key technical support around 0.450, awaiting a potential upside breakout.
Can Cleanaway (ASX: CWY) Re Rate Higher as Margins Expand and Strategy 2030 Takes Hold?
Cleanaway (ASX: CWY) is rebuilding momentum through upgraded EBIT guidance, margin expansion, and a stronger strategic framework, with valuation support emerging as earnings and free cash flow accelerate.
Can Aristocrat Leisure (ASX: ALL) Extend Its Margin Expansion as Gaming Strength and Interactive Momentum Converge?
Aristocrat Leisure (ASX: ALL) delivers strong HY26 growth, expanding margins and cash generation across Gaming, Social Casino and iLottery, positioning the company for sustained earnings momentum and a multi year re rating. With NPATA up 8% (16% in constant currency), EBITDA up 6%, and segment profit expanding in constant currency, ALL has shown an expanding competitive advantage, strong cash generation, and a clear path to sustained NPATA growth.
...